The effect of metabolic syndrome and/or hyperglycemia on outcomes of acute ischemic stroke patients treated with intravenous thrombolysis

Abstract

Backgrounds and Objectives:

The impact of metabolic syndrome (MetS)/hyperglycemia on the clinical outcomes of ischemic stroke treated with intravenous thrombolysis (IVT) remains controversial. This study aimed to determine the risks conferred by MetS and hyperglycemia to clinical outcomes in acute ischemic stroke patients treated with IVT.

Method:

Three hundred forty-three ischemic stroke patients treated with IVT were prospective recruited and stratified into four groups: neither, MetS only, hyperglycemia only, or both. The primary outcome was the 3-month poor functional outcome (PFO) which was defined as a 3-month modified Rankin Score (mRS) score ≧3. The secondary outcome included the hemorrhagic transformation (HT) and symptomatic intracranial hemorrhage (sICH) after IVT.

Results:

MetS was recognized in 197 (57.43%) patients. During the first 24 h after IVT, 44 (12.83%) patients had HT, of which 17 had sICH. Three-month PFO was found in 98 (28.57%) patients. After adjustment for potential confounders, MetS (odds ratio (OR) = 3.140, 95% confidence interval (CI) = 1.724–5.718) was independently associated with PFO. However, neither MetS nor its components were associated with 24-h HT or sICH. In the further subgroup analysis, we used the “neither” group as reference and found that the presence of both MetS and hyperglycemia (OR = 3.192, 95% CI = 1.338–7.615) and the presence of hyperglycemia only (OR = 2.097, 95% CI = 1.052–4.179) were significantly related to the 3-month PFO.

Conclusion:

MetS is an independent risk factor on 3-month PFO in acute ischemic stroke patients treated with IVT. Compared with “neither,” hyperglycemia only or concurrent with MetS was associated with an elevated risk of PFO after receiving IVT.

Keywords

Metabolic syndrome stroke outcome intravenous thrombolysis

Get full access to this article

View all access options for this article.

References

Grundy

Cleeman

Daniels

, et al Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific statement. Circulation 2005; 112: 2735–2752.

Santaniemi

Ukkola

Malo

Bloigu

Kesäniemi

. Metabolic syndrome in the prediction of cardiovascular events: the potential additive role of hsCRP and adiponectin. Eur J Prev Cardiol 2014; 21: 1242–1248.

Rodriguez-Colon

Duan

Caulfield

Jin

Liao

. Metabolic syndrome clusters and the risk of incident stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2009; 40: 200–205.

Vona

Gambardella

Cittadini

Straface

Pietraforte

. Biomarkers of oxidative stress in metabolic syndrome and associated diseases. Oxid Med Cell Longev 2019; 2019: 8267234.

Bas

Ozdemir

. The effect of metabolic syndrome and obesity on outcomes of acute ischemic stroke patients treated with systemic thrombolysis. J Neurol Sci 2017; 383: 1–4.

Sobolewski

Brola

Szczuchniak

Fudala

Kozera

. Intravenous thrombolysis with recombinant tissue-type plasminogen activator for acute ischemic stroke in patients with metabolic syndrome. J Stroke Cerebrovasc Dis 2015; 24: 1787–1792.

Arenillas

Sandoval

de la Ossa

, et al The metabolic syndrome is associated with a higher resistance to intravenous thrombolysis for acute ischemic stroke in women than in men. Stroke 2009; 40: 344–349.

Zhu

McClure

Lau

, et al Recurrent vascular events in lacunar stroke patients with metabolic syndrome and/or diabetes. Neurology 2015; 85: 935–941.

Johnston

Bruno

Pauls

, et al Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the SHINE randomized clinical trial. JAMA 2019; 322: 326–335.

10.

Pan

Cai

Jing

, et al Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the CHANCE study (Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events). Stroke 2017; 48: 3006–3011.

11.

Adams

Jr Bendixen

Kappelle

, et al Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993; 24: 35–41.

12.

Qiu

, et al Assessment of endovascular treatment for acute basilar artery occlusion via a nationwide prospective registry. JAMA Neurol 2020; 77: 561–573.

13.

Larrue

von Kummer

Müller

Bluhmki

. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32: 438–441.

14.

Hacke

Kaste

Bluhmki

, et al Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317–1329.

15.

Cull

Jensen

Retnakaran

Holman

. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation 2007; 116: 2119–2126.

16.

Wang

Zhang

, et al Metabolic syndrome: prevalence and risk factors in southern China. J Int Med Res 2010; 38: 1142–1148.

17.

Zhang

Sun

Ding

, et al Metabolic syndrome augments the risk of early neurological deterioration in acute ischemic stroke patients independent of inflammatory mediators: a hospital-based prospective study. Oxid Med Cell Longev 2016; 2016: 8346301.

18.

Chen

Pan

Jing

, et al Recurrent stroke in minor ischemic stroke or transient ischemic attack with metabolic syndrome and/or diabetes mellitus. J Am Heart Assoc 2017; 6: e005446.

19.

Ois

Gomis

Rodríguez-Campello

. Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke. Stroke 2008; 39: 1717–1721.

20.

Lee

, et al Association between metabolic syndrome and functional outcome in patients with acute ischaemic stroke. Eur J Neurol 2014; 21: 177–179.

21.

Ding

, et al Association of homeostasis model assessment of insulin resistance, adiponectin, and low-grade inflammation with the course of the metabolic syndrome. Clin Biochem 2015; 48: 503–507.

22.

Rha

Saver

. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38: 967–973.

23.

Berkhemer

Fransen

PSS

Beumer

, et al A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015; 372: 11–20.

24.

Dorado

Arenillas

López-Cancio

, et al Metabolic syndrome predicts refractoriness to intravenous thrombolysis in acute ischemic stroke. J Stroke Cerebrovasc Dis 2015; 24: 2605–2612.

25.

Van Rooy

Pretorius

. Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke. Thromb Res 2015; 135: 434–442.

26.

Carter

Cymbalista

Spector

Grant

and EuroCLOT Investigators. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27: 2783–2789.

27.

Menon

Smith

Coutts

, et al Leptomeningeal collaterals are associated with modifiable metabolic risk factors. Ann Neurol 2013; 74: 241–248.

28.

Nicoli

Lafaye de Micheaux

Girard

. Perfusion-weighted imaging-derived collateral flow index is a predictor of MCA M1 recanalization after i.v. thrombolysis. Am J Neuroradiol 2013; 34: 107–114.

29.

Calleja

García-Bermejo

Cortijo

, et al Insulin resistance is associated with a poor response to intravenous thrombolysis in acute ischemic stroke. Diabetes Care 2011; 34: 2413–2417.